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An o v e lt r i - n-butyl(IV) derivative of 2-thiobarbituric acid (HTBA) of formula [(n-Bu)3Sn(TBA)·H2O] (1) has been synthesized
and characterized by elemental analysis and 119Sn-NMR and FT-IR spectroscopic techniques. The crystal structure of complex 1
has been determined by single crystal X-ray diﬀraction analysis at 120(2)K. The geometry around Sn(IV) is trigonal bipyramidal.
Three n-butyl groups and one oxygen atom from a deprotonated 2-thiobarbituric ligand are bonded to the metal center. The ge-
ometry is completed with one oxygen from a water molecule. Compound 1 exhibits potent, in vitro, cytotoxicity against sarcoma
cancer cells (mesenchymal tissue) from the Wistar rat, polycyclic aromatic hydrocarbons (PAH, benzo[a]pyrene) carcinogenesis.
In addition, the inhibition caused by 1, in the rate of lipoxygenase (LOX) catalyzed oxidation reaction of linoleic acid to hyperox-
olinoleic acid, has been also kinetically and theoretically studied. The results are compared to that of cisplatin.
Copyright © 2008 VasiliosI. Balas et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The increasing interest in the bioinorganic chemistry of
organotin(IV) compounds has led to extended studies on
their interactions with diﬀerent types of biomolecules such
as carbohydrates, nucleic acid derivatives, amino acids and
peptides [1, 2]. The organotin(IV) compounds are exhibit-
ing signiﬁcant antitumor activity [1–8]. More particularly,
organotin(IV) complexes with ligands containing phenolic
–OH groups and a heterocyclic nitrogen {N} donor atom
comprise an interesting class of such complexes because they
containanamidegroup[9,10].Surprisingly,onlyfeworgan-
otin(IV) complexes of this type have been structurally char-
acterized up to now [10]. Recently, the inhibition caused
by organotin(IV) complexes of thioamide ligands towards
lipoxygenase (LOX) catalyzed oxidation reaction of linoleic
acid to hyperoxolinoleic acid in relation with the antitumor
activity caused by these complexes was studied [3–8]a n da
mechanism of free radicals was proposed. 2-Thiobarbituric
acid, on the other hand, is a reagent in use for the detection
of lipid hydroperoxides and lipid oxidation [11, 12].
In order to investigate further the mechanism of cyto-
toxic activity of organotin(IV)-thioamide complexes, we re-
port here the synthesis of a new complex with formula [(n-
Bu)3Sn(TBA)·H2O] (1) (HTBA is the 2-thiobarbituric acid)
(Scheme 1). The complex has been characterized by elemen-
tal analysis and 119Sn-NMR and FT-IR spectroscopic tech-
niques. The structure of the complex was also determined
by X-ray crystallography at 120(2)K. The tri-n-butlyltin
derivative was chosen, since it is known to possess antipar-
asitic properties [1, 2]. 2-Thiobarbituric acid, a well-known
reagent in use for the determination of the lipid peroxidation
in biological systems, is chosen in order to possibly increase
theLOXinhibitionactivityoforganotinmoiety[3–8,11,12].
The anticancer cell screening results of the compound tested
are also reported. The inhibition caused by 1, in the rate of
lipoxygenase (LOX) catalyzed oxidation reaction of linoleic
acid to hyperoxolinoleic acid has also been kinetically and
theoretically studied.
Complex 1 was synthesized by reacting a methanolic so-
lution of tri-n-butlyltin(IV) chloride (n-Bu)3SnCl with an
aqueous solution of 2-thiobarbituric acid (HTBA) which
contains an equimolar amount of potassium hydroxide. The
structure was solved by direct methods SHELXS97 [13]a n d2 Bioinorganic Chemistry and Applications
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successive diﬀerence Fourier syntheses. Reﬁnement applied
full-matrix least-squares methods SHELXL97 [14]. Atomic
scattering factors for neutral atoms and real and imagi-
nary dispersion terms were taken from International Ta-
bles for X-ray Crystallography [15]. Intensity data for the
colorless crystals were collected on a Nonius Kappa CCD
diﬀractometer with graphite-monochromated MoKα radia-
tionat120(2)K.C16H32N2O3SSn,MW=451.19,monoclinic
inP21/n,a=11.0956(2),b=17.3425(4),c =11.1879(2) ˚ A,β=
95.3080(10)◦, V = 2143.60(7) ˚ A3, Z = 4, D= 1.398Mg/m3,
μ= 1.303mm−1,ﬁ n a lR = 0.0247 for 4906 unique observed
[F2 > 2 σ (F2)] diﬀractometer data. Measurements of in vitro
cells toxicity have been carried out in preliminary repetitions
according to the method described in literature [3–8].
The ir spectrum of complex 1 shows distinct absorp-
tion at 2959cm−1 due to the C–H bond vibrations of n-
butyl groups, at 1546 and 1398cm−1, which are assigned to
ν(CN) vibrations (thioamide I and II bands) and at 1194
and 906cm−1, which are attributed to the ν(CS) vibrations
(thioamide III and IV bands). The corresponding thioamide
I and II bands in crystalline HTBA appear at 1527 and
1350cm−1 while thioamide bands III and IV are observed at
1154 and 801cm−1 [16].
119Sn-NMR spectrum of complex 1, in DMSO-d6 solu-
tion, shows a resonance signal at 5.7ppm indicating a four
coordinated Sn atom [17]. Since the corresponding value for
the (n-Bu)3SnCl in DMSO-d6 is found to be at 2.7ppm [18],
this is indicative of a partial positive charged Sn atom in 1
(see crystal structure). Chemical shifts δ are given in ppm
referencedto119Sn-Me4Sn.Thestabilityof 1inDMSO-d6 so-
lution was veriﬁed by recording its 1H-NMR spectrum, as a
function of time. Free HTBA ligand shows a resonance sig-
nal at 12.1ppm (s, H(N)), 4.9ppm (s, H(C)), and 3.5 ppm
(s, H(C)) (Scheme 1)[ 16] which are shifted at 10.9ppm (s,
H(N)) and at 4.2ppm (s, H(C)) in case of 1 . The signal at
3.5ppm (s, H(C)) could not be observed in the 1H-NMR
of the complex since enol-keton tautomerims can not be es-
tablished in case of coordinated HTBA. Resonance signals at
1.55ppm (t), 1.28ppm (m), 1.09ppm (m), and at 0.87ppm
(t) were assigned to the H(C) of the n-butyl group.
Adiagramof 1aswellasselectedbondlengthsandangles
are shown in Figure 1(a).
The structure of compound 1 consists of one (n-Bu)3
Sn(IV) moiety bonded with a de-protonated 2-thiobarb-
ituric acid (HTBA) molecule and a water molecule. The Sn1
atom exhibits a distorted trigonal bipyramidal conﬁguration
with C (5), C (9), and C (13) occupying the equatorial and
O2 from HTBA ligand and O3 from the water molecule, oc-
cupying the axial positions. According to Reedijk’s geometric
parameter (τ = (β − α)/60 where α is the greatest and β the
second greatest bond angle around the metal center) [19] the
calculated τ value is 0.94, being equal to zero for perfectly
tetragonal pyramidal geometry and unity for perfectly trigo-
nal pyramidal [19].
The Sn1–O2 bond distance of 2.2287(14) ˚ Ai si na c -
cordance with that found in [Ph2(pyO)SnCH2Sn(OH)Ph2]2
(where pyO = anion of 2-hydroxypyridine), [10] (Sn–O=
2.227(2) ˚ A). The two C–O bond distances (C1–O2=
1.274(2), and C3–O1 = 1.261(2) ˚ A, resp.) are almost equal.
The C1–C2 and C2–C3 bond lengths of 1.386(3) and
1.394(3) ˚ A, respectively, are also equal. This bond distri-
bution in 1 (shown in Scheme 2) leads to a zwitterionic
form of the compound (Scheme 2) and is in agreement with
119Sn-NMR, in DMSO-d6 solutions. The molar conductance
(Λm) value of the complex in DMSO solution (5 10−3M) is
5.3(cm−1mole−1Ω−1) showing that the complex is not con-
ducting in solution conﬁrming the stability of the zwiterion,
also in solution [20].
Contrary to this coordination mode, HTBA coordinates
to the gold(I) ion through its deprotonated form with the
negative charge to be located at the sulphur atom forming
neutral complexes [21].
Extended intermolecular hydrogen bonding interact-
ions {N2[H96]···S1ii = 3.2692(17), N1[H97]···O1I =
2.790(2), O3[H98]···O1iii = 2.630(2), and O3[H99]···
S1iv = 3.2302(17) ˚ A, respectively, where the symmetry trans-
formations used to generate equivalent atoms are (i) −x+1,
−y, −z+2, (ii) −x+2, −y, −z+2, (iii) x+1/2, −y+1/2, z−1/2,
(iv) −x+3/2, y+1/2, −z+3/2} lead to the supramolecular as-
sembly of the complex (Figure 1(b)).
The inﬂuence of complex 1 on the oxidation of linoleic
acid by the enzyme LOX was studied in a wide concen-
tration range. The degree of LOX activity (A, %) in the
presence of the complex was calculated according to the
method described previously [3–8]. Figure 2 gives the in-
hibitory eﬀect of complex 1 at various concentrations. It
is shown that the catalytic activity of LOX was decreased
in the presence of low concentrations (about 5–75μM)
of the complex 1 (IC50 = 25μM) while no such activity
was shown for cisplatin [3–8]. These values are compa-
rable to the ones found for other similar Sn(IV) com-
plexes. For example, the IC50 values found for the organ-
otin compounds tested towards LOX, were 26 and 14μMf o r
[(C6H5)2SnCl(HMNA)] and [(C6H5)3Sn(MNA)Sn(C6H5)3
(acetone)] (H2MNA= 2-thiobarbituric acid), respecti-
vely [6], 19, 16, and 21μM for ([(C6H5)3Sn(MBZT)]),
([(C6H5)3Sn(MBZO)]), ([(C6H5)3Sn(CMBZT)]) (MBZT=
2-mercapto-benzothiazole, MBZO= 2-mercapto-benzoxa-
zole and CMBZT= 5-chloro-2-mercapto-benzothiazole),
respectively [3], 10, 13, and 14μM for ([(C6H5)2Sn
(CMBZT)2]), ([(n-C4H9)2Sn(CMBZT)2]), and ([(CH3)2Sn
(CMBZT)2]), respectively [3] and 61.3, 26.2, 20.5, and
16.9μM for ([(CH3)2Sn(PMT)2]), ([(n-C4H9)2Sn(PMT)2]),
([(C6H5)2Sn(PMT)2]), and ([(C6H5)3Sn(PMT)]) (PMT =
2mercapto-pyrimidine), respectively [4].
In order to investigate further the complex-protein in-
teractions, we performed computational molecular docking
studies for the complexes. The binding energy (E) of theVasiliosI. Balas et al. 3
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Figure 1: (a) Diagram of compound 1 together with the atomic numbering scheme. Selected bond lengths (˚ A) and angles [◦]; Sn1–O2=
2.2287(14), Sn1–O1= 2.3410(15), Sn1–C5= 2.136(2), Sn1–C9= 2.1372(18), Sn1–C13= 2.1408(19), C1–O2= 1.274(2), C1–C2= 1.386(3),
C2–C3= 1.394(3), C3–O1= 1.261(2), C1–N2= 1.389(3), C3–N1= 1.393(3), C5–Sn1–C9= 120.41(8), C5–Sn1–C13= 120.97(8), C9–Sn1–
C13= 118.24(8), C5–Sn1–O2= 91.12(7), C9–Sn1–O2 = 89.76(7), C13–Sn1–O2= 95.23(7), C5–Sn1–O3= 91.14(7), C9–Sn1–O3= 87.87(7),
C13–Sn1–O3= 84.81(7), O2–Sn1–O3= 177.33(6). (b) 3D hydrogen bonded network.4 Bioinorganic Chemistry and Applications
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Scheme 2: A possible bond and charge distribution on the atoms
in 1.
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Figure 2: Inhibitory eﬀect of 1 towards LOX.
substrate (S = linoleic acid) to its binding site in the en-
zyme LOX (E) when ES is the complex formed was E =
−7.89kcal/mole [6]. The corresponding binding energies of
the inhibitor (I)a r ec a l c u l a t e dt o−6.92 and −6.37 kcal/mol
forESIandEI,respectively.Figure 3showsthebindingsiteof
compound 1 towards LOX. Compound 1 binds to both ESI
and EI complexes at the same pocket where the strong in-
hibitors of LOX bind [3], supporting its strong inhibition ac-
tivity, found experimentally. Since high inhibition activity of
LOXhasbeendetectedforallcytotoxicorganotin(IV)-thione
compounds tested previously, [3–8] such a strong activity is
also expected for this compound.
Complex1wasalsotestedforantitumorpotentialagainst
sarcoma cancer cells (mesenchymal tissue) from the Wistar
rat, polycyclic aromatic hydrocarbons (PAH, benzo[a]
pyrene) carcinogenesis. Cytotoxic activity for complex 1 was
evaluated as % percentage of the cell survived in variable
concentrations 50 to 1000nM (or 0.05 to 1μM) of the com-
plex after 24 hours. The IC50 value found for 1 was 125nM
or 0.125μM indicating very strong cytotoxic activity against
leiomyosarcoma cells as compared to cisplatin (IC50 = 4-
5μM[ 8]). The corresponding IC50 values of other organ-
otin(IV) complexes found against leiomyosarcoma cells were
0.005μM for [(C6H5)3Sn(MNA)Sn(C6H5)3 (acetone)] [7],
1.5–3, 1.3–3, and 0.5–0.8μM for ([(C6H5)3Sn(MBZT)]),
([(C6H5)3Sn(MBZO)]), ([(C6H5)3Sn(CMBZT)]) (MBZT =
2-mercapto-benzothiazole, MBZO = 2-mercapto-benzoxa-
zole and CMBZT= 5-chloro-2-mercapto-benzothiazole), re-
spectively [3], 0.3–0.5, 0.6–0.8, and 5–7.5μM for ([(C6H5)2
Sn(CMBZT)2]), ([(n-C4H9)2Sn(CMBZT)2]), and ([(CH3)2
Sn(CMBZT)2]), respectively [3] and 20–60, 0.7, 1-2, and
(ESI)
(a)
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Figure 3:Bindingsitesofinhibitor1inlipoxygenase.The“walls”of
this binding pocket concist of the amino acid residues: ESI:76ALA,
533ARG, 767ARG, 128ASN, 769ASN, 760ASP, 768ASP, 78GLU,
75GLY, 249LEU, 110LYS, 15MET, 108PHE, 762VAL; EI:76ALA,
533ARG, 767ARG, 128ASN, 760ASP, 768ASP, 761GLU, 247GLY,
248HIS, 246LEU, 249LEU, 110LYS, 762VAL.
0.1μM for ([(CH3)2Sn(PMT)2]), ([(n-C4H9)2Sn(PMT)2]),
([(C6H5)2Sn(PMT)2]), and ([(C6H5)3Sn(PMT)]) (PMT =
2mercapto-pyrimidine), respectively [4].
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